Results 191 to 200 of about 26,607 (237)
Some of the next articles are maybe not open access.
New England Journal of Medicine, 1993
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Thrombosis in acute promyelocytic leukemia
Thrombosis Research, 2013Compared to bleeding, major thromboses are a less commonly encountered problem in acute promyelocytic leukemia (APL), and our knowledge about the epidemiology of major thromboses in APL stems mainly from individual case reports. The purpose of this study was to provide a better understanding of the epidemiology of APL-related thrombosis as a first step
Armin, Rashidi +3 more
openaire +2 more sources
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
New England Journal of Medicine, 2013 All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%.
Giuseppe Avvisati +2 more
exaly +2 more sources
Management of acute promyelocytic leukemia
Current Oncology Reports, 2002Acute promyelocytic leukemia (APL) has become the most potentially curable subtype of acute myeloid leukemia (AML) in adults. With current treatment strategies that incorporate all-trans retinoic acid (ATRA), long-term disease-free survival and potential cure rates of 70% to 80% can be expected.
Martin S, Tallman, Chadi, Nabhan
openaire +2 more sources
Acute Promyelocytic Leukemia: A Perspective
Clinical Lymphoma Myeloma and Leukemia, 2017Treatment of patients with acute promyelocytic leukemia has significantly improved with the introduction of target specific agents all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with long term survival a reality for the majority of patients.
Farhad Ravandi, Richard Stone
openaire +2 more sources
The biology of acute promyelocytic leukemia
Current Oncology Reports, 2001Acute promyelocytic leukemia (APL) is a disease associated with fusion oncoproteins invariably involving the retinoic acid receptor (Raralpha). Retinoic acid induces differentiation in APL cells and is successfully used in conjunction with chemotherapy to treat and cure a significant percentage of patients with APL.
K K, Mann, W, Shao, W H, Miller
openaire +2 more sources
Coagulopathy of Acute Promyelocytic Leukemia
Acta Haematologica, 2001Life-threatening bleeding is frequent in acute leukemias, particularly in acute promyelocytic leukemia (APL), a distinct subtype of acute myelogenous leukemia, characterized by the balanced reciprocal translocation between chromosomes 15 and 17.
A, Falanga, T, Barbui
openaire +2 more sources
Acute promyelocytic leukemia in childhood
Current Oncology Reports, 2009Acute promyelocytic leukemia (APL) is a relatively rare form of acute myelogenous leukemia (AML). In the United States, APL in children constitutes only 5% to 10% of AML. Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation ...
John, Gregory, James, Feusner
openaire +2 more sources
Current Treatment Options in Oncology, 2000
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
Acute promyelocytic leukemia in children
Medical and Pediatric Oncology, 1981AbstractSixteen children (ages 2–17) with acute promyelocytic leukemia (APL) were studied retrospectively. Diagnosis was based on clinical features and morphological criteria of the FAB classification. Bleeding diathesis was the predominant presenting symptom (>85%), associated with laboratory findings of disseminated intravascular coagulation (DIC).
K W, Chan, P G, Steinherz, D R, Miller
openaire +2 more sources